How effective is Exkivity (mobocertinib) for NSCLC?
Note: On October 2, 2023 Takeda Pharmaceuticals announced the voluntary withdrawal of Exkivity from the U.S and global markets. Exkivity did not meet the primary endpoint of the Phase 3 EXCLAIM-2 confirmatory trial and did not meet the requirements of the Accelerated Approval granted by the FDA for the treatment of NSCLC.
Key Points
- The effectiveness of Exkivity was determined by looking at the overall response rate (ORR) and the duration of response (DoR) to treatment.
- In clinical studies, 32 of 114 patients (28%) with non-small cell lung cancer (NSCLC) had a partial response to Exkivity treatment. In these patients, the response to treatment lasted for about 17.5 months.
- Close to 59% of patients who responded had a response that lasted at least 6 months. Median overall survival was 24 months (2 years).
Exkivity study results
In Sept., 2021, the FDA granted accelerated approval to Exkivity (mobocertinib) based on a clinical research study known as Study 101. This study included 114 patients with non-small cell lung cancer (NSCLC) that had spread to other parts of the body and could not be removed by surgery. These patients had EGFR exon 20 insertion mutations in their lung cancer, as determined by a special test.
Patients were on or had previously received a chemotherapy treatment that contained platinum, but their disease had worsened. In the study, the participants received a 160 mg oral dose of Exkivity once daily until their lung cancer worsened or they had side effects they could not tolerate.
The effectiveness of Exkivity was determined by looking at the overall response rate (ORR) and the duration of response (DoR). The ORR looks at how many people using Exkivity saw a tumor response like shrinkage. The DoR measures how long the response lasted.
Overall, about 28% of the people (32/114) had a partial response to Exkivity treatment and the response lasted for about 17.5 months. Close to 59% of patients who responded (19/32) had a response that lasted at least 6 months. The median overall survival was 24 months (2 years). Median means that half the people lived longer than 24 months, and the other half lived less than 24 months.
On October 2, 2023 Takeda Pharmaceuticals announced the voluntary withdrawal of Exkivity from the U.S and global markets as Accelerated Approval confirmatory studies did not meet the required endpoints.
Related Questions
- How do Exkivity and Rybrevant compare for NSCLC?
- Is small cell or non-small cell lung cancer worse?
- Is non-small cell lung cancer hereditary?
Exkivity common side effects
The most common side effects (>20%) reported in Study 101 for Exkivity were:
- Diarrhea
- Rash
- Mouth sores
- Vomiting
- Decreased appetite
- Infection of skin around nails
- Nausea
- Muscle or bone pain
- Dry skin
- Feeling Tired
Exkivity labeling carries a Boxed Warning for QTc prolongation and Torsades de Pointes (types of dangerous heart rhythms), warnings for certain types of lung or heart toxicity, and diarrhea.
What is Exkivity?
Exkivity (mobocertinib) is an oral kinase inhibitor formerly approved for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations that has progressed on or after platinum-based chemotherapy. It was a first-in-class oral therapy specifically designed to target EGFR Exon 20 insertion mutations.
When available, Exkivity came as a 40 mg capsule. The recommended dose was 160 mg (4 capsules) orally once daily, with or without food.
This is not all the information you need to know about Exkivity (mobocertinib) for safe and effective use and does not take the place of your doctor’s directions. Review the full product information and discuss any questions you have with your doctor or other health care provider.
References
- Takeda Provides Update on Voluntary Withdrawal Exkivity (mobocertinib). Drugs.com. October 2, 2023. Accessed Oct 31, 2023 at https://www.drugs.com/clinical_trials/takeda-provides-update-voluntary-exkivity-mobocertinib-21074.html
- Zhou C, Ramalingam SS, Kim TM, et al. Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial. JAMA Oncol. 2021 Dec 1;7(12):e214761. doi: 10.1001/jamaoncol.2021.4761. Erratum in: JAMA Oncol. 2022 Feb 24;: PMID: 34647988; PMCID: PMC8517885.
- FDA grants accelerated approval to mobocertinib for metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations. US Food and Drug Administration (FDA). Accessed May 4, 2022 at https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-mobocertinib-metastatic-non-small-cell-lung-cancer-egfr-exon-20
- Exkivity. Dosing and Patient Management Guide. Takeda Pharmaceuticals. Lexington, MA. Accessed May 4, 2022 at https://www.exkivityhcp.com/files/EXKIVITY-Dosing-and-Patient-Management-Guide.pdf
Read next
Related medical questions
- What type of lung cancer is Vizimpro used to treat?
- How long does it take for Keytruda to work?
- Why give Taxol (Paxel) before carboplatin?
- What is the difference between Opdivo and Keytruda?
- Pembrolizumab vs. nivolumab: How do they compare?
- What is Paxel called in the USA?
- How effective is Lumakras, what's the survival rate?
- How effective is Tabrecta?
- How does erlotinib work (mechanism of action)?
- How long can I take Gilotrif (afatinib) for?
- What is the difference between Mvasi and Avastin?
- How does Retevmo work?
- Will Tabrecta cure lung cancer?
- Are there cost-saving programs for Tecentriq?
- Is Tabrecta a chemotherapy drug?
- What is the mechanism of action for Alecensa (alectinib)?
- Can Tarceva (erlotinib) cure lung cancer?
- Is Gilotrif (afatinib) a chemotherapy drug?
- Is atezolizumab (Tecentriq) a chemotherapy or immunotherapy drug?
- How effective is atezolizumab (Tecentriq)?
- How effective is Alecensa for ALK-positive NSCLC?
- How long do you take Alecensa for?
- How does Gilotrif (afatinib) work?
- How does pemetrexed work?
- How does Rybrevant work?
- Does atezolizumab (Tecentriq) cause hair loss?
- How long does it take for Xalkori to work?
- How to pronounce Xalkori?
- How does Alecensa work?
- Why is it called non-small cell lung cancer?
Drug information
Related support groups
- Exkivity (2 questions, 3 members)
- Mobocertinib (1 questions, 4 members)
- Non-Small Cell Lung Cancer (52 questions, 70 members)